Sentences with phrase «between placebo group»

Another ninety - century study where male bodybuilders were given 2,5 mg boron supplement (probably too small amount for any effect) daily for 7 weeks noted no significant differences in male hormones between placebo group.

Not exact matches

Results will be compared between the Vascepa and placebo groups.

There were no significant differences in adverse events between groups, which were reported by 2 % of children taking the three types of honey compared to 1 % taking placebo.

Meta - analysis revealed no significant differences between LCPUFA and placebo groups in BSID Mental Developmental Index (MDI) scores at 18 months (MD 0.06, 95 % CI -2.01 to 2.14; I2 = 75 %; four trials; N = 661) and no significant differences in BSID Psychomotor Development Index (PDI) scores at 18 months (MD 0.69, 95 % CI -0.78 to 2.16; I2 = 61 %; four trials; N = 661).

Researchers report that the only substantial difference in safety outcomes between the placebo and bococizumab groups was injection site reactions, which is also the result of the immunologic response in some patients.

The randomised, blinded phase of the trial found no difference between the statin and placebo groups for erectile dysfunction (1.86 % vs 2.14 % per year).

At the end of the study, there was no difference between the cinnamon and placebo groups in terms of glucose or cholesterol.

Eliminating these 10 people, who were evenly divided between placebo and treated groups, showed that efficacy increased to nearly 78 %.

The primary endpoint of death and non-fatal heart attack at 30 days was no different between the two groups (7 percent in the aspirin group and 7.1 percent in the placebo group); however, major bleeding was significantly higher in aspirin - treated patients than in the placebo group (4.6 percent vs. 3.7 percent).

With no possibility of rejection, offers were lower overall ($ 3.68 on average), and there was no statistical difference between the oxytocin and placebo groups.

However, the late postmenopausal group showed essentially the same rates of CIMT progression between those taking estradiol and those taking the placebo.

Simvastatin was generally well tolerated and serious adverse events were similar between the two groups (20 % placebo vs 13 % simvastatin).

Overall, the researchers found that there was no significant difference in bone mass between the babies born to women supplemented with vitamin D compared with those who had taken placebo (mean bone mass 61 · 6g in vitamin D group vs 60 · 5g in the control).

Researchers found significant differences in overall survival between those on the drug and those on the placebo in the older age group.

The randomized, double - blind, parallel - group, placebo - controlled studies were a collaboration between Roche and several research institutions around the world.

For the acetazolamide group (n = 187), compared with the placebo group (n = 193), no significant between - group differences were found for median duration of mechanical ventilation -LRB--16.0 hours), duration of weaning off mechanical ventilation -LRB--0.9 hours), or for other respiratory parameter - values (respiratory frequency, tidal volume, and minute ventilation), although daily changes of serum bicarbonate and number of days with metabolic alkalosis decreased significantly more in the acetazolamide group.

In the primary analysis, change in NT - proBNP levels from baseline to week 12 was not significantly different between the pooled vericiguat group and placebo.

Although baseline (placebo) measures of striatal DA D2 receptor availability did not differ between groups, the marijuana abusers showed markedly blunted responses when challenged with MP.

The researchers found that the rates of subclinical atherosclerosis progression, as measured by changes in common carotid artery intima - media thickness or coronary artery calcium, did not differ significantly between men assigned to the testosterone or placebo groups.

Discontinuation rates due to all causes were similar between the zonisamide and placebo groups (risk ratio, 1.29; 95 % CI, 0.90 to 1.84; p = 0.16).

While zonisamide also decreased both UPDRS Part II (off - time) and UPDRS total scores compared to placebo (UPDRS Part II [off - time] scores: WMD, — 0.79; UPDRS total scores: WMD, — 2.51), there were no significant differences in other secondary outcomes between the two groups.

There were no substantive differences between study groups at baseline; 8506 women were randomized into the estrogen plus progestin group and 8102 into the placebo group (Table 1a).

Between August 2012 and June 2015, 27 percent fewer women in the dapivirine ring group were infected with HIV than in the placebo group, the study's authors found.

Most controlled studies have made use of a modest dose of just 1 g / day of vitamin C. From all published research, the combined effect has revealed a difference between the groups taking vitamin C and the groups taking a placebo which is highly significant, suggesting a real biological effect.

During a baseline night in which blood was not drawn, there was no difference in sleep quality between the progesterone and placebo groups.

Rugby players were given a tribulus terrestris supplement or a placebo; both groups gained mass and fat free mass after five weeks of training but there was no difference between the groups.

Overall, the difference in weight loss between the pyruvate supplement and placebo groups was not large, amounting to approximately 1.1 - 1.6 kg (about 2 - 3 lb) additional weight loss in the pyruvate groups.

For this study, ten male and ten female athletes were assigned to creatine or placebo groups, where, before and after the three - day creatine supplementation period, they were assessed on repeated sprint performance and thigh muscle volume - the creatine group was given 0.35 grams of creatine per kilogram of fat free mass, and all subjects completed six maximal ten second cycle sprints with 60 seconds of recovery in between.

In one study published in the American Journal of Clinical Nutrition, a group of 700 volunteers between the ages of 60 and 74 were given placebo or a daily combination of 400 micrograms of folic acid and 100 micrograms of vitamin B12.

After 12 months, there was no difference between the vitamin group and the placebo group.

So what the science tells us is that there truly is no real division between the body and the mind and emotions, it's all part of the same web, and we know this from the research studies that have been done, groups at Harvard, Johns Hopkins, a lot of the big, very reputable universities are now actually doing research on this, and there are even journals, scientific and medical journals exploring what we call psychosomatic medicine, in other words the placebo effect.

In a larger study, adults with multiple risk factors and LDL choles - terol concentrations above 4.14 mmol / L or between 3.37 and 4.14 mmol / L were randomized to one of seven groups to receive either oatmeal or oat bran at various levels or a placebo control (Davidson et al., 1991).

After 2 to 6 weeks of treatment with 20 g / d of fructo - oligosaccharides or placebo, symptoms of irritable bowel syndrome improved more in the placebo group than in the fructooligosaccharide group; however, there was no difference between the groups after con - tinuous treatment for 12 weeks.

However, it should be noted that there was no significant difference in plasma progesterone levels between the placebo - and alcohol - receiving groups after naltrexone administration.

Although there were no significant differences in teacher or parent rating scores between the zinc and placebo group in phase 1 or 2 of the trial, data from phase three showed that the group receiving zinc 15 mg twice a day required a 37 % lower dosage of AMPH when compared to placebo [18,48].

The study also didn't have a placebo group, and studies on neurofeedback that include a placebo sometimes show no difference between using neurofeedback and not using it, says Giesbrecht.

There were no significant differences between patients in both placebo and fluoxetine groups on measures of general psychiatric symptoms, global functioning or self - reported depressive symptom measurements (Moldenhauer & Melnyk, 1999).